Comparison · NCT02680756-18a208a2
Oral Ferric Iron Compound vs Intravenous Iron: Number of Patients With Treatment-emergent Adverse Events (AEs)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Oral Ferric Iron Compound vs Intravenous Iron: Number of Patients With Treatment-emergent Adverse Events (AEs). Trial comparisons, record NCT02680756-18a208a2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02680756-18a208a2
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.591 | 0.504 | 0.672 | wilson | |
| Risk in group 2 | 0.358 | 0.278 | 0.447 | wilson | |
| Risk difference, group 1 minus group 2 | 0.232 | 0.108 | 0.347 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.65 | 1.25 | 2.18 | log | |
| Odds ratio, group 1 over group 2 | 2.58 | 1.54 | 4.32 | log | |
| Number needed to treat, for one more participant with the outcome on Oral Ferric Iron Compound than on Intravenous Iron | 4.31 | 2.88 | 9.28 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Oral Ferric Iron Compound | 30 mg capsules to be taken orally twice a day~Ferric Maltol | 75 | 127 | OG000 |
| Group 2 | Intravenous Iron | Administered as per the local SmPC/PI~Ferric Carboxymaltose | 43 | 120 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- OTHER_PRE_SPECIFIED
- Title
- Number of Patients With Treatment-emergent Adverse Events (AEs)
- Description
- Number of Patients with Treatment-emergent Adverse Events (AEs).
- Time frame
- Baseline to Week 52
- Population
- 3 subjects were randomised to IV iron but were given ferric maltol in error.
Source ClinicalTrials.gov
Trial
- Title
- Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD
- NCT number
- NCT02680756
- Phases
- PHASE3
- Conditions
- Anemia, Iron-Deficiency, Inflammatory Bowel Disease, Crohn's Disease
- Interventions
- Ferric Maltol, Ferric Carboxy Maltose
- Lead sponsor
- Shield Therapeutics
- Results first posted
- 2020-02-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02680756?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02680756-18a208a2